RELEASE: Philips highlights the benefits of its ICP solutions with the use of ultra-low contrast during CSC

The company's solutions record instantaneous blood flow measurements and/or intravascular ultrasound (IVUS) images along with real-time fluoroscopy to aid interventionalists in diagnosis and treatment.

RELEASE: Philips highlights the benefits of its ICP solutions with the use of ultra-low contrast during CSC

The company's solutions record instantaneous blood flow measurements and/or intravascular ultrasound (IVUS) images along with real-time fluoroscopy to aid interventionalists in diagnosis and treatment

· The main advantage of these techniques is the possibility of performing complex interventions "without being limited by the volume of contrast that we can use", acknowledges the interventional cardiologist Nieves Gonzalo

Ultra-low-contrast PCI solutions integrate seamlessly with Azurion, the Philips image-guided therapy system

Madrid, November 16, 2022 – Royal Philips, a leading health technology company, presents its innovations in ultra-low contrast percutaneous coronary intervention (ULCPCI) during the CSC 2022 (Coronary and Structural Course), a practical course for coronary intervention professionals that is held during these days in Madrid. Solutions offered by Philips record instantaneous blood flow measurements and/or intravascular ultrasound (IVUS) images along with real-time fluoroscopy to assist interventionalists in diagnostic and treatment procedures.

For professionals, the main advantage of the ULCPCI technique is the possibility of performing complex coronary interventions adapted to the needs of the patient "without being limited by the volume of contrast that we can use," as recognized by Dr. Nieves Gonzalo, an interventional cardiologist at the San Carlos Clinical Hospital. "In addition, these techniques are tremendously useful in situations in which it is not possible to inject contrast due to the presence of dissections, both spontaneous and iatrogenic," she points out.

Possibility of PCI in more complex patients

The ability to perform these procedures using a very small amount of contrast media allows more groups of patients to perform PCI. "It can be very useful, for example, for the treatment of patients at high risk of developing contrast-induced acute kidney injury, such as those with chronic kidney disease, low ejection fraction, anemia, etc.", as the interventional cardiologist points out.

It can also be very useful in situations where contrast injections are not possible due to the presence of coronary dissections. "Something common in the context of treatment of chronic total occlusions," according to Dr. Gonzalo. In general, and in her opinion, the use of these techniques that reduce contrast dependency makes it possible to complete more complex coronary interventions.

Solutions integrated in the Azurion platform

The company's exclusive ultra-low contrast percutaneous coronary intervention solutions integrate seamlessly into the link, providing the right tools for practitioners to diagnose, decide, guide, treat and confirm PCI success.

During a conventional PCI procedure, contrast media is injected into the patient's coronary arteries to perform angiography, and additional fluoroscopy is used during the procedure to help interventionists navigate their guidewires and catheters. In order to maintain visibility of the arteries, this guidance often requires repeated injections of contrast media, which increases the toxic load on the patient's kidneys.

Dynamic Coronary Roadmap software eliminates the need to inject additional contrast media by overlaying the preoperative angiogram on real-time motion-compensated 2D fluoroscopic images. “This technology reduces dependence on contrast by providing us with the silhouette of the moving blood vessel and allowing adjustment of the placement of balloons, stents or other devices without the need to inject contrast”, explains Dr. Gonzalo.

While this solution helps interventional clinicians direct guidewires and catheters to the injury site, the IntraSight Series 7 precision guidance system, which makes tools such as iFR, IVUS, and co-registration easy to use and access, streamlines evaluation of the lesion, simplifies the assessment of the size of the vessels and allows the application of a more precise treatment.

“The co-registration of IVUS and angiography makes it possible to characterize the morphology of the lesion and determine the size of the necessary stent. Once the stent is implanted, the IVUS can be used to verify its good result and guide optimization, if required. Once again, coregistration can be performed using the angioplasty guidewire, without the need to inject contrast," explains Dr. Gonzalo.

Taking advantage of the framework of this practical course for professionals that revolves around live cases and that is held during these days in Madrid, Philips presents its contrast saving techniques and the latest intravascular imaging technologies. “Our solutions allow interventionists to perform ULCPCI with greater confidence and clarity, obtaining good results and reducing risk and complications for the patient”, concludes Rosa María Rial, head of the Coronary devices business at Philips Ibérica.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHI) is a leading healthcare technology company focused on improving people's health and well-being, and facilitating better outcomes across the health cycle, from habits health and prevention, to diagnosis, treatment and home care. Philips draws on its advanced technology and in-depth clinical and consumer insights to offer integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as consumer health and home care. Philips has recorded sales of €17.2 billion in 2021 and employs approximately 78,000 employees, with business operations and services in more than 100 countries. All Philips news can be found in our News Center

For more information:

Cesar Garcia Requena

Brand

Philips Iberica

Tel : 670 264 471

Email: cesar.garcia.requena@philips.com

Ruben Marcos / Daniel Calvo

Europe Press Communication

Tel : 91 359 26 00

E-mail : rubenmarcos@europapress.es / danielcalvo@europapress.es

Yorum yapabilmek için üye girişi yapmanız gerekmektedir.

Üye değilseniz hemen üye olun veya giriş yapın.

NEXT NEWS